Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer | Zendy

Thomas Callender | Zendy; Mark Emberton | Zendy; Stephen Morris | Zendy; Paul D.P. Pharoah | Zendy; Nora Pashayan | Zendy

Open Access

Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer

Author(s) -

Thomas Callender,

Mark Emberton,

Stephen Morris,

Paul D.P. Pharoah,

Nora Pashayan

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.37657

Subject(s) - overdiagnosis , medicine , cohort , prostate cancer , prostate cancer screening , biopsy , magnetic resonance imaging , quality adjusted life year , cancer , cost effectiveness , oncology , gynecology , prostate specific antigen , radiology , risk analysis (engineering)

This decision analytical model uses a hypothetical cohort of men in England to evaluate whether magnetic resonance imaging before biopsy for prostate cancer screening is associated with improvements in benefit-harm and cost-effectiveness profiles compared with biopsy-first screening.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research